The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study has developed predictive risk scores for cardiovascular disease (CVD) and chronic kidney disease (CKD, defined as confirmed estimated glomerular filtration rate [eGFR] ≤ 60 ml/min/1.73 m2) events in HIV-positive people. We hypothesized that participants in D:A:D at high (>5%) predicted risk for both CVD and CKD would be at even greater risk for CVD and CKD events.
Methods and findings
We included all participants with complete risk factor (covariate) data, baseline eGFR > 60 ml/min/1.73 m2, and a confirmed (>3 months apart) eGFR < 60 ml/min/1.73 m2 thereafter to calculate CVD and CKD risk scores. We calculated CVD and CKD event rates by predicted 5-year CVD and CKD risk groups (≤1%, >1%–5%, >5%) and fitted Poisson models to assess whether CVD and CKD risk group effects were multiplicative. A total of 27,215 participants contributed 202,034 person-years of follow-up: 74% male, median (IQR) age 42 (36, 49) years, median (IQR) baseline year of follow-up 2005 (2004, 2008). D:A:D risk equations predicted 3,560 (13.1%) participants at high CVD risk, 4,996 (18.4%) participants at high CKD risk, and 1,585 (5.8%) participants at both high CKD and high CVD risk. CVD and CKD event rates by predicted risk group were multiplicative. Participants at high CVD risk had a 5.63-fold (95% CI 4.47, 7.09, p < 0.001) increase in CKD events compared to those at low risk; participants at high CKD risk had a 1.31-fold (95% CI 1.09, 1.56, p = 0.005) increase in CVD events compared to those at low risk. Participants’ CVD and CKD risk groups had multiplicative predictive effects, with no evidence of an interaction (p = 0.329 and p = 0.291 for CKD and CVD, respectively). The main study limitation is the difference in the ascertainment of the clinically defined CVD endpoints and the laboratory-defined CKD endpoints.
We found that people at high predicted risk for both CVD and CKD have substantially greater risks for both CVD and CKD events compared with those at low predicted risk for both outcomes, and compared to those at high predicted risk for only CVD or CKD events. This suggests that CVD and CKD risk in HIV-positive persons should be assessed together. The results further encourage clinicians to prioritise addressing modifiable risks for CVD and CKD in HIV-positive people.
Why was this study done?
- Access to combination antiretroviral therapy has increased the life expectancy of HIV-positive people.
- Despite this success, there is evidence that HIV-positive people may experience an earlier onset of comorbidities (e.g., cardiovascular disease [CVD] and chronic kidney disease [CKD]) in comparison with their HIV-negative peers.
- The D:A:D study has developed specific models to predict the risk for CVD and CKD events in HIV-positive people.
- This study was designed to investigate whether HIV-positive people at high risk for both CVD and CKD are at even greater risk for CVD and CKD events, and may therefore warrant particularly close clinical attention and management.
What did the researchers do and find?
- The D:A:D study is a prospective observational study that combines 11 cohorts of >49,000 HIV-positive people followed prospectively since 1999.
- We performed a study that included the 27,215 participants with the requisite data to calculate their D:A:D CVD and CKD risk scores. We calculated the CVD and CKD event rates by predicted 5-year CVD and CKD risk groups (≤1%, >1%–5%, >5%) and analysed whether CVD and CKD risk group effects were multiplicative.
- We found that people at high predicted risk for both CVD (>5%) and CKD (>5%) events have substantially greater risks for both CVD and CKD events compared with those at low predicted risk for both outcomes and those at high predicted risk for CVD or CKD events alone.
What do these findings mean?
- HIV-positive people not uncommonly have high predicted CVD and/or CKD risk; these interact to create substantial risks for future morbid events.
- Our results suggest that CVD and CKD risk in HIV-positive people should be assessed together.
- The results should further encourage clinicians to prioritise addressing modifiable risks for CVD and CKD in HIV-positive people.
Citation: Boyd MA, Mocroft A, Ryom L, Monforte Ad, Sabin C, El-Sadr WM, et al. (2017) Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. PLoS Med14(11): e1002424. https://doi.org/10.1371/journal.pmed.1002424
Academic Editor: Steven G. Deeks, San Francisco General Hospital, UNITED STATES
Received: June 8, 2017; Accepted: October 3, 2017; Published: November 7, 2017
Copyright: © 2017 Boyd et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The D:A:D Study Steering Committee encourages the submission of concepts for research projects. Concepts can be submitted for review by the D:A:D Steering Committee using an online research concept, please see http://www.cphiv.dk/OngoingStudies/DAD/Submit-research-concept. Once submitted the research concept will undergo review by the D:A:D SC for evaluation of the scientific relevance, relevance to the D:A:D study, design, statistical power and feasibility and overlap with already approved projects. Upon completion of the review, feedback will be provided to the proposer(s). In some circumstances, a revision of the concept may be requested. If the concept is approved for implementation, a writing group will be established consisting of the proposers (up to 3 persons that were centrally involved in the development of the concept) and members of the D:A:D Steering Committee (or other appointed cohort representatives) Statistical department and Coordinating Center. All persons involved in the process of reviewing these research concepts are bound by confidentiality. Requests can be made to the D:A:D Coordination Office att. Camilla Hatleberg (Camilla.email@example.com). To obtain data, please contact Dorthe Raben, Director of Research Coordination (Dorthe.firstname.lastname@example.org).
Funding: Data on Adverse Events (D:A:D) Study:The D:A:D study was supported by the Highly Active Antiretroviral Therapy Oversight Committee (HAARTOC), a collaborative committee with representation from academic institutions, the European Agency for the Evaluation of Medicinal Products, the United States Food and Drug Administration, the patient community, and pharmaceutical companies with licensed anti-HIV drugs in the European Union: AbbVie, Bristol-Myers Squibb, Gilead Sciences Inc., ViiV Healthcare, Merck & Co Inc. and Janssen Pharmaceuticals. Supported also by a grant [grant number DNRF126] from the Danish National Research Foundation (CHIP & PERSIMUNE); by a grant from the Dutch Ministry of Health, Welfare and Sport through the Center for Infectious Disease Control of the National Institute for Public Health and the Environment to Stiching HIV Monitoring (ATHENA); by a grant from the Agence nationale de recherches sur le sida et les hépatites virales [ANRS, Action Coordonnée no.7, Cohortes] to the Aquitaine Cohort; The Australian HIV Observational Database (AHOD) is funded as part of the Asia Pacific HIV Observational Database, a program of The Foundation for AIDS Research, amfAR, and is supported in part by a grant from the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) [grant number U01-AI069907] and by unconditional grants from Merck Sharp & Dohme; Gilead Sciences; Bristol-Myers Squibb; Boehringer Ingelheim; Janssen-Cilag; ViiV Healthcare. The Kirby Institute is funded by The Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, The University of New South Wales; by grants from the Fondo de Investigación Sanitaria [grant number FIS 99/0887] and Fundación para la Investigación y la Prevención del SIDA en Espanã [grant number FIPSE 3171/00], to the Barcelona Antiretroviral Surveillance Study (BASS); by the National Institute of Allergy and Infectious Diseases, National Institutes of Health [grants number 5U01AI042170-10, 5U01AI046362-03], to the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA); by primary funding provided by the European Union’s Seventh Framework Programme for research, technological development and demonstration under EuroCoord grant agreement n° 260694 and unrestricted grants by Bristol-Myers Squibb, Janssen R&D, Merck and Co. Inc., Pfizer Inc., GlaxoSmithKline LLC, (the participation of centres from Switzerland is supported by The Swiss National Science Foundation (Grant 108787)) to the EuroSIDA study; by unrestricted educational grants of AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Pfizer, Janssen Pharmaceuticals to the Italian Cohort Naive to Antiretrovirals (The ICONA Foundation); and financed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation (grant #148522) and by the SHCS research foundation. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: MB has received research grants, paid to his institution from Merck Sharp & Dohme and Gilead Sciences. MB has also received honoraria for participation on HIV advisory boards and preparation and delivery of educational materials from Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme and ViiV Healthcare. AM has received honoraria, travel support, speaker fees and consultancy fees from ViiV, BMS, BI, Gilead, and Wragge LLC; AP received speaker fees for a 2015 conference for Gilead Sciences; ML has received unrestricted research grants, paid to his institution, from Boehringer Ingelhiem, Gilead Sciences, Merck Sharp & Dohme, Bristol-Myers Squibb, Janssen-Cilag, ViiV HealthCare; ML has also received consultancy and presentation fees from Gilead Sciences, and DSMB sitting fees from Sirtex Pty Ltd; PR through his institution has received independent scientific grant support from Gilead Sciences, Janssen Pharmaceuticals Inc, Merck & Co, Bristol-Myers Squibb and ViiV Healthcare; PR has served on a scientific advisory board for Gilead Sciences and ViiV Healthcare, as well as on a data safety monitoring committee for Janssen Pharmaceuticals Inc, and has chaired a scientific symposium by ViiV and received remuneration; CS's institution has received a grant from the D:A:D Oversight Committee for the analysis and co-ordination of the D:A:D Study; CS has also received personal fees from Gilead Sciences, ViiV Healthcare and Janssen-Cilag for the membership of Data Safety and Monitoring Boards, Advisory Boards, Speaker Panels and for the preparation of educational materials.
Abbreviations: BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; D:A:D, Data Collection on Adverse Events of Anti-HIV Drugs; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HBV, hepatitis B virus; HCV, hepatitis C virus; HDL, high-density lipoprotein; IDU, injecting drug use; IRR, incidence rate ratio; N(t)RTI, nucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; pyrs, person-years
Combination antiretroviral therapy has transformed the lives of HIV-positive people. Over the past 20 years in high-income countries, rates of opportunistic diseases have declined and life expectancy has reached levels similar to that of the HIV-negative population [1–4]. However, there is evidence suggesting that people living with HIV experience greater and earlier onset of comorbidities compared with their HIV-negative peers [5–7]. The relative extent to which this observation relates to a higher prevalence of behaviours and risks associated with such comorbidities, increased levels of immune activation and coagulopathy despite sustained virological suppression, antiretroviral treatment, and/or other mechanisms remains unclear [8,9].
In the general population, it is well established that chronic kidney disease (CKD) is an important and independent risk factor (covariate) for cardiovascular disease (CVD) . It has been argued that CKD should be considered a coronary risk factor, and that aggressive risk factor reduction for other CVD risk factors should be part of standard therapy for patients with CKD .
CVD in turn is associated with CKD. This may be mediated by the development of atherosclerosis, or may result as a consequence of shared risk factors with CKD such as hypertension and diabetes mellitus. It is well recognised that the effects of comorbidity may be greater than the effects of the sum of risk of each disease, and that their co-existence may lead to more severe illness, poorer prognosis, and premature death .
In HIV-positive people, a similarly strong relationship between CKD and CVD has been reported . The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) collaboration has developed HIV-specific predictive risk models for CVD  and CKD  in an attempt to help guide care in these individuals. We hypothesized that participants in D:A:D at high (>5%) predicted risk for both CVD and CKD would be at even greater risk for CVD and CKD events, and may therefore warrant particularly close clinical attention and management.
The D:A:D study is a prospective observational study that combines 11 cohorts of HIV-positive people. Its objective is to establish whether the use of combination antiretroviral therapy is associated with an elevated risk of CVD, end-stage renal disease (ESRD), liver disease, cancer, and death. The 11 cohorts contribute data on 49,717 participants enrolled at 212 clinics in Europe, the US, Argentina, and Australia. The standardised dataset includes information on socio-demographics, AIDS events and death, known CVD risk factors, height and weight, laboratory markers, antiretroviral treatment history, estimated glomerular filtration rate (eGFR) (Cockcroft—Gault equation), and treatments including those prescribed for CVD risk.
The main analyses in this study were performed according to a prospectively established statistical analysis plan (S2 Text). The non-prospectively defined analyses were those investigating the covariates of the CVD risk score as predictors for CKD events adjusted for CKD risk group, the covariates of the CKD risk score as predictors for CVD events adjusted for CVD risk group, and the prevalence of diabetes at baseline according to predicted CKD and CVD risk group.
All participating cohorts in the D:A:D study followed local national guidelines/regulations regarding patient consent and ethical review.
In this study we included individuals for whom a complete set of risk covariate data was available after 1 January 2004 as required by both the D:A:D CVD and CKD risk equations, except for missing data for exposure to viral hepatitis C and family history of CVD, in which case these were imputed to be negative (thus slightly underestimating CVD risk in these individuals). All those included in the analysis had an eGFR > 60 ml/min/1.73 m2 at baseline and an eGFR ≤ 60 ml/min/1.73 m2 observed subsequently on at least 2 consecutive occasions at least 3 months apart. We used definitions of endpoints indicating CVD and CKD as defined in previous D:A:D publications [13,14], but note that CVD events were centrally validated clinical events (myocardial infarction, stroke, and invasive cardiac procedures), whereas CKD events were based on confirmed laboratory criteria.
Patient follow-up was censored at the earliest of the following: last eGFR, last visit plus 6 months, or 1 February 2015. We excluded participants with a previous history of CVD, baseline eGFR ≤ 60 ml/min/1.73 m2, or a CVD or CKD event that occurred within 30 days of baseline. We included CVD events and follow-up after the definition of a CKD event had been met and CKD events after the definition of a CVD event had been met.
We calculated the 5-year predicted risk for CKD and CVD using the D:A:D risk equations [13,14]. The CVD equation includes age, sex, diabetes, CVD family history, current and former smoking, total cholesterol, high-density lipoprotein (HDL) cholesterol, systolic blood pressure, current CD4 count, current receipt of abacavir, and cumulative exposure to protease inhibitors (PIs) and nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs). We censored PI and N(t)RTI at 3 and 7 years, respectively, as this reflects the range of data on which the models were developed and so avoids over-predicting risk. The CKD equation includes age, sex, exposure to HIV through injecting drug use, hepatitis C coinfection, baseline eGFR, nadir CD4 count, hypertension, prior CVD and diabetes, adjustment for current receipt of unboosted atazanavir or ritonavir-boosted lopinavir, and a higher adjustment for tenofovir disoproxil fumarate, ritonavir-boosted atazanavir and any other PI.
We stratified the 5-year predicted CKD and CVD risk into groups as ≤1%, >1%–5%, and >5%. We did this rather than use predicted risk as a continuous measure for 2 reasons. First, this reflects how clinicians and their patients use these risk equations, categorising predicted risk into groups that then indicate possible interventions. Second, using risk groups in this fashion allows clear presentation of the rates of CKD and CVD events in each predicted risk group. We deliberately chose not to use the low, moderate, and high CKD risk groups defined by Mocroft et al.  in order that the CVD and CKD risk groups could be interpreted in the same fashion. We performed a secondary analysis of events using the Framingham equation, recalibrated to the D:A:D study as described in a previous publication , to assess whether the results would be similar compared to the primary analysis. We also examined CKD and CVD events using predicted risks as continuous covariates as a sensitivity analysis.
We calculated CKD and CVD event rates by CKD and CVD risk group. We fitted Poisson models to assess whether CKD and CVD risk group effects are additive or multiplicative. In an attempt to assess how the predicted CVD risk score was contributing to prediction of CKD events, we investigated predictors of CKD events, fitting the CKD risk score group and then each of the covariates in the CVD risk score that are not included in the CKD risk score. We also investigated predictors of CVD events, fitting the CVD risk score group and then each of the covariates in the CKD risk score that are not included in the CVD risk score.
Of the 49,717 individuals enrolled in the D:A:D study, 27,215 (55%) had the required complete covariate data after 1 January 2004 and were included in this analysis, contributing 202,034 person-years (pyrs) of follow-up.
Characteristics of the 27,215 individuals included at baseline, defined as the first time each individual had complete CVD and CKD risk factor data available after 1 January 2004, are shown in Table 1. The median (IQR) baseline year of follow-up was 2005 (2004, 2008). The cohort was 74% male, with a median (IQR) age of 42 (36, 49) years. Fifty percent were smokers at baseline, and 3.8% had a diagnosis of diabetes mellitus. The median (IQR) 5-year predicted CKD risk was 1.1% (0.6%, 3.7%), and the median (IQR) 5-year predicted CVD risk was 1.6% (0.8%, 3.3%).
Of the 1,415 people with a CKD event and 918 people with a CVD event, 154 (10.9%) experienced both types of event. Eighty-six (56%) of those who had both events experienced the CVD event first, and 67 (44%) the CKD event first. In 1 person the CKD and CVD event occurred on the same day. The majority of the CKD and CVD events (117, 76%) occurred 1 or more years apart.
Overall CVD and CKD risk
The numbers of participants in each predicted risk group combination are expressed in Table 2. Of the 3,560 people with a 5-year predicted CVD risk > 5%, 3,331 (94%) were men and 229 (6%) were women. In these 3,331 men there were 528 CKD events (rate 23.0 per 1,000 pyrs), and in the 229 women there were 53 CKD events (rate 37.3 per 1,000 pyrs).
CKD event rates according to CKD and CVD risk
We observed 1,415 CKD events during follow-up, an overall rate of 7.00 per 1,000 pyrs (95% CI 6.6–7.7 per 1,000 pyrs). CKD event rates by predicted CKD and CVD risk group are shown in Fig 1, indicating that within each CKD risk group, the CKD event rate increases with higher predicted CVD risk.
CKD, chronic kidney disease; CVD, cardiovascular disease; pyrs, person-years.
This multiplicative effect of CKD and CVD predicted risk group on CKD events is confirmed by the Poisson regression models (Table 3), which show a highly statistically significant association between predicted CVD risk group and CKD events, after adjustment for CKD risk group. In these models there was no statistical evidence of an interaction between the predicted CKD and CVD risk groups, suggesting that the effects are multiplicative (i.e., additive on a log scale). This means, for example, that for an individual with a high predicted 5-year risk of both CKD and CVD, the incidence rate ratio (IRR) for CKD events would be 13.81 multiplied by 5.63, which equals 77.75, compared with an individual at low predicted risk for both CKD and CVD.
The CKD event rates by predicted Framingham CVD and CKD risk strata were similar to the findings in the primary analysis (S1 Table).
CVD event rates according to CKD and CVD risk groups
There were 918 CVD events documented during follow-up, an overall rate of 4.5 per 1,000 pyrs (95% CI 4.2–4.8 per 1,000 pyrs). CVD event rates by predicted CVD and CKD risk groups are shown in Fig 2. This figure shows large increases in CVD event rates with increasing predicted CVD risk, as would be expected. But there is also some evidence of increasing CVD events with increasing predicted CKD risk.
CKD, chronic kidney disease; CVD, cardiovascular disease; pyrs, person-years.
The Poisson regression models did confirm a statistically significant association between higher predicted CKD risk group and CVD events after adjustment for predicted CVD risk (Table 3). But the magnitude of this association was smaller than was seen for the association between predicted CVD risk group and CKD events. Again, there was no statistical evidence of an interaction between predicted CVD and CKD risk groups.
The CVD event rates by predicted Framingham CVD and CKD risk strata were also similar to the findings made in the primary analysis (S2 Table).
Investigating covariates of the CVD risk score as predictors of CKD events
The relationship between the covariates of the CVD risk score and prediction of CKD events (adjusted for CKD risk group) is summarised in Table 4. We found that total plasma cholesterol level was associated with risk of a CKD event (IRR 1.48 per unit log total cholesterol, 95% CI 1.20, 1.83, p < 0.001), as were baseline CD4 count (IRR 0.90, 95% CI 0.86, 0.95, p < 0.001) and cumulative exposure to a PI (IRR 1.11 per year exposure, 95% CI 1.06, 1.15, p < 0.001) or to an N(t)RTI (IRR 1.05 per year exposure, 95% CI 1.03, 1.08, p < 0.001). We did not find statistically significant relationships for having a family history of CVD, being an ex- or current smoker, HDL cholesterol, or currently receiving abacavir.
In a multivariate analysis, after adjusting the covariates for each other as predictors of CKD events, we found similar associations as for the analysis adjusted only for CKD risk group, although the association for receiving a PI lost statistical significance (IRR 1.04, 95% CI 0.99, 1.10, p = 0.149).
Investigating covariates of the CKD risk score as predictors of CVD events
After adjustment for CVD risk group, we found 1 covariate in the CKD risk score that was associated with CVD events (Table 5). Higher nadir CD4 count was associated with a reduced risk of CVD events: IRR 0.94 per 100 cells (95% CI 0.091, 0.98, p = 0.002). We did not find associations between predicted CKD risk and HIV exposure through injecting drug use, baseline eGFR, or being coinfected with viral hepatitis C.
Diabetes by predicted CKD and CVD risk
Diabetes is a key covariate in both the CKD and CVD risk scores. Therefore, we were interested in exploring the prevalence of diabetes in the CKD and CVD predicted risk groups (Table 6). The prevalence of diabetes at baseline increased markedly with higher predicted CVD risk group. The association was less clear with CKD risk group, but of the 1,585 people at >5% predicted risk for both CVD and CKD, 366 (23.1%) had been diagnosed with diabetes.
We conducted sensitivity analyses assessing the predicted CKD and CVD risk scores as continuous measures rather than in groups. After adjustment for 5-year predicted CKD risk, 5-year CVD predicted risk was significantly associated with CKD events: IRR 1.065 per 1% increase (95% CI 1.058, 1.072, p < 0.001). Five-year CKD predicted risk was not significantly associated with CVD events after adjustment for 5-year CVD predicted risk: IRR 1.005 per 1% increase (95% CI 1.000, 1.011, p = 0.052). These analyses suggest that the multiplicative effects of predicted CKD and CVD risk groups on CKD and CVD events are not simply due to a loss of precision by categorising the predicted risks as ≤1%, >1%–5%, and >5%.
In this analysis we found that HIV-positive people with high predicted CVD or CKD risk were at significant risk for a future CVD or CKD event, and that this risk was multiplicative for those with greater degrees of risk. For instance, we observed a far higher CKD event rate for those at high risk (>5%) for both CVD and CKD (44.0 per 1,000 pyrs) compared to those at low risk for both (0.5 per 1,000 pyrs) and those at intermediate risk for both (5.1 per 1,000 pyrs). We found that the CKD event rate in those with a high CKD risk was highly sensitive to the degree of CVD risk, with a CKD event rate of 7.1, 21.9, and 44.0 events per 1,000 pyrs for a CVD risk of ≤1%, >1%–5%, and >5%, respectively. For CVD events we found that event rates were multiplicative in that there was a gradient from those at low risk for both events (0.45 per 1,000 pyrs) to those at high risk for both events (16.50 per 1,000 pyrs), with those at intermediate risk in between.
It is widely acknowledged that there are complex relationships between CVD and CKD, and that the risks that mediate both of these conditions can interact, leading to more severe illness and poorer prognosis . Our results are consistent with this understanding in that we found that both chronic diseases were associated with an elevated risk for the other. Overall our results suggest that among people living with HIV, the association between CVD risk and a future CKD event is stronger than the association between CKD risk and a future CVD event, and that the strength of the association may be particularly marked in those who are at high risk for both CVD and CKD. This is a novel finding, as the opposite has consistently been noted in the general population, where those with CKD are at markedly elevated risk for CVD. For the general population, for instance, when adjusted for traditional cardiovascular risk factors, impaired kidney function and raised concentrations of albumin in urine increase the risk of CVD 2- to 4-fold . In interpreting these findings, it should be noted that this difference may be a function of the difference in the definition of the 2 disease endpoints used in the study; CVD is a clinical event adjudicated centrally according to specific criteria, whereas CKD is defined by the presence of impaired renal function as indicated by a laboratory biomarker (eGFR) observed over 2 consecutive occasions at least 3 months apart. This laboratory-based definition is thereby a sensitive measurement that captures people with true CKD but may also include people with transient decreases in eGFR not indicative of irreversible renal function deterioration.
In terms of the risk factors for development of CKD events in those with CVD risk, we found that total cholesterol level and cumulative PI and N(t)RTI use raised the risk of CKD events, and that a higher baseline CD4 count was associated with a lower rate of future CKD events. These findings are consistent with results previously reported in the D:A:D cohort [15–18]. We found that cumulative exposure to N(t)RTIs predicts CKD events, despite tenofovir exposure being included as an adjustment in the CKD predicted risk score. This may be because tenofovir exposure was included in the CKD predicted risk model as an acute effect rather than an effect that increases with increasing exposure.
For CVD events according to CKD risk, we did not find an association between eGFR and CVD risk. This is not consistent with findings in the general community. However, the failure to find such an association may be due to effective management of renal insufficiency, with a resultant decrease in the risk of CVD in this population. This finding also seems inconsistent with previous D:A:D analyses . This apparent inconsistency is likely explained by the fact that the present analysis was based on a single baseline eGFR with participants selected with eGFR in a relatively healthy range (>60 ml/min/1.73 m2), whereas previous analyses were time updated and included far lower eGFR values.
It is recognised that both CKD and CVD are largely preventable conditions and that modifying and controlling their risk factors will reduce the risk of onset of both diseases. Despite this evidence and much effort over the past decade to focus attention on reducing CVD risk in HIV-positive people, a lack of attention to the management of CVD in people living with HIV has been documented . A recent modelling analysis within the ATHENA cohort examined the impact of several interventions, such as earlier antiretroviral treatment, smoking cessation, and anti-hypertensive or lipid-lowering treatment, on future CVD events among HIV-positive people . The results suggested that all the selected interventions, but especially smoking cessation and blood pressure and serum lipid control, would have a positive effect in reducing CVD.
We performed an analysis that assessed the extent to which the presence of diabetes in the participants may provide at least a partial explanation of the multiplicative risks we observed in those with higher degrees of risk, and particularly in those with a high risk for both events. We found that nearly a quarter of those with a high 5-year CKD and CVD risk had been diagnosed with diabetes, compared to very few individuals diagnosed with diabetes (0.4%) in the low CKD and CVD risk groups. This confirms that diabetes is a powerful risk factor for poor outcomes in HIV-positive people, as in the general community, and it behoves all clinicians to adequately screen, diagnose, treat, and, above all, prevent this complication to facilitate the optimal longevity and quality of life in HIV-positive people.
Our study has some limitations. Prediction models are limited by restrictions in the available data, and some variables that may affect CKD and CVD risk were not available for analysis (e.g., inflammatory markers). In this analysis, the risk equations were applied to the datasets that were largely used to develop them. It may be, therefore, that the equations predict more accurately in D:A:D data than they would in other independent datasets, and this may limit the generalisability of our findings. Both equations, however, were validated: the CVD equation using internal—external cross-validation, and the CKD equation on independent datasets. The CVD and CKD endpoints used in this analysis are quite different. CVD is a serious clinical event, subject to central validation, whereas CKD is an earlier, less serious event based on a confirmed laboratory marker. As noted above, compared with the more specific adjudicated CVD endpoint, the CKD definition may be capturing a broader set of events that might include true episodes of chronic and progressive CKD but also transient events in people who may be temporarily systemically unwell, hospitalised, and/or undergoing a medical procedure, all of which may lead to episodic decreases in eGFR without this necessarily resulting in persistent renal dysfunction. We attempted to minimise the possibility of miscategorising people with CKD by requiring there to be at least 2 consecutive eGFR measurements ≤ 60 ml/min/1.73 m2 to make the diagnosis. However, the ‘softer’ definition of CKD may at least partially explain the finding that the magnitude of association was greater when analysing CKD events by CVD risk than when analysing CVD events by CKD risk. It is uncertain how the results might have differed if a hard clinical endpoint for renal disease, such as ESRD, had been used. Such an approach, however, was not possible in our analyses, as a prediction tool for ESRD in HIV-positive people is not available, and the number of ESRD events in D:A:D is not large. In the D:A:D database, we are unable to distinguish cases of either CKD or CVD that were a direct result of a previous event.
In conclusion, we have shown that HIV-positive people not uncommonly have high predicted CVD and/or CKD risk, and that these interact to create substantial risks for future morbid events. We found that people at high predicted risk for both CVD and CKD have substantially greater risks for both CVD and CKD compared with those at low predicted risk for both, and those at high predicted risk for only CVD or only CKD. This suggests that CVD and CKD risk in HIV-positive persons should be assessed together. These data also suggest that the primary prevention and effective management of these comorbidities, prioritising those interventions that have been repeatedly shown to be effective in the general population, will convey the same if not greater benefits for the population of HIV-positive people. Primary prevention and the effective management of comorbidities should be incorporated into the development of guidelines and defining future research priorities for HIV-positive people.
S1 Table. CKD event rates by predicted Framingham CVD and CKD risk strata.
S2 Table. CVD event rates according to predicted Framingham CVD and CKD risk strata.
S1 Text. Full list of members of the D:A:D Steering Committee and Study Group.
For a list of the full members of the D:A:D Steering Committee and Study Group, please refer to S1 Text.
The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned in the list of funders.
- 1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–60. pmid:9516219
- 2. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med. 2007;146:87–95. pmid:17227932
- 3. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8(12):e81355. pmid:24367482
- 4. Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349–56. pmid:28501495
- 5. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–96. pmid:17135583
- 6. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67. pmid:17617273
- 7. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–6. pmid:21998278
- 8. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203. pmid:18942885
- 9. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807. pmid:26192873
- 10. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Lambers Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–52. pmid:23727170
- 11. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81. pmid:20483451
- 12. Ryom L, Lundgren JD, Ross M, Kirk O, Law M, Morlat P, et al. Renal impairment and cardiovascular disease in HIV-positive individuals: the D:A:D Study. J Infect Dis. 2016;214:1212–20. pmid:27485357
- 13. Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2016;23:214–23. pmid:25882821
- 14. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, et al. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015;12:e1001809. pmid:25826420
- 15. DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte Ad, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;26;356:1723–35. pmid:17460226
- 16. D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417–26. Erratum in: Lancet. 2008;372:292. pmid:18387667
- 17. Data Collection on Adverse Events of Anti-HIV Drugs Study Group, Sabin CA, d’Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, et al. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis. 2008;46:1101–10. pmid:18461712
- 18. Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016;3:e23–32. pmid:26762990
- 19. van Zoest RA, van der Valk M, Wit FW, Vaartjes I, Kooij KW, Hovius JW, et al. Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy. Eur J Prev Cardiol. 2017;24:1297–307. pmid:28578613
- 20. Smit M, van Zoest RA, Nichols BE, Vaartjes I, Smit C, van der Valk M, et al. Cardiovascular disease prevention policy in HIV: recommendations from a modelling study. Clin Infect Dis. 2017 Oct 6. pmid:29029103